cord blood
-
Trial Report REGENECYTE cord blood cell therapy in post-COVID syndrome: a phase IIa randomized, placebo-controlled trial, 2026, Huang et al
REGENECYTE cord blood cell therapy in post-COVID syndrome: a phase IIa randomized, placebo-controlled trial [Line breaks added] Background Post-COVID syndrome affects a substantial proportion of individuals worldwide and imposes significant healthcare and economic burdens. Fatigue is one of...- forestglip
- Thread
- cord blood hematopoietic cell transplantation long covid regenecyte stem cells
- Replies: 0
- Forum: Long Covid research